Vancouver, Canada – July 15, 2026 – Onco-Innovations Limited (CBOE: ONCO) (“Onco” or the “Company”) announces that it has entered into three loan agreements with certain lenders providing for loans to the Company in the aggregate principal amount of up to CAD$280,000 (collectively, the “Loans”).

Two of the Loans are from arm’s length shareholders of the Company (together, the “Shareholder Loans”), pursuant to which the Company may make demand for the principal amounts of up to CAD$20,000 and CAD$60,000, respectively. The Shareholder Loans bear interest at a rate of 15% per annum, calculated monthly, and are repayable on demand. The Shareholder Loans may be prepaid in whole or in part at any time without premium or penalty, with any prepayment to be credited first to accrued but unpaid interest and then to principal.

The third Loan is from Dr. Islam Mohamed, the Chief Medical Officer of the Company, in the amount of CAD$200,000 (the “Other Loan”). The Other Loan bears interest at a rate of 1% per month, calculated monthly, and is repayable in two equal tranches of CAD$100,000, with the first tranche due on or before September 13, 2026 and the second tranche due on or before November 13, 2026, subject to earlier repayment on demand or acceleration upon an event of default. If any amount is not repaid when due, an additional 2% per month will accrue on overdue amounts, resulting in an aggregate default rate of 3% per month on overdue amounts. The Other Loan may be prepaid in whole or in part upon written notice, subject to a prepayment fee equal to 2% of the amount prepaid, plus all interest that would otherwise have accrued and been payable through the applicable maturity date.

The Company expects to use the proceeds of the Shareholder Loans for general working capital purposes. The proceeds of the Other Loan may only be used for specific third-party research and development vendors identified in the Other Loan agreement.

As Dr. Mohamed is the Chief Medical Officer of the Company, he is a “related party” of the Company. Accordingly, the Other Loan constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company will rely on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 set out in sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, on the basis that the fair market value of the Other Loan does not exceed 25% of the Company’s market capitalization, as determined in accordance with MI 61-101.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”

Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy, Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

The Cboe has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”), including, without limitation, statements regarding: the expected use of proceeds of the Loans; the repayment of the Loans; the Company’s ability to satisfy its obligations under the Loans; and the Company’s business objectives and planned research and development activities.

Forward-looking statements are often identified by words such as “intend”, “expect”, “anticipate”, “believe”, “may”, “will”, “plan”, “potential” and similar expressions. These statements are based on current expectations, estimates and assumptions made by management in light of its experience and perception of historical trends.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Such factors include, without limitation: the Company’s ability to use the proceeds of the Loans as currently anticipated; the Company’s ability to repay the Loans when due or on demand; the Company’s ability to satisfy its obligations under the Loans; the availability of additional financing on acceptable terms; general capital market conditions; the Company’s ability to execute its business and research and development plans; and other risks and uncertainties disclosed in the Company’s continuous disclosure filings available under its profile on SEDAR+.

Forward-looking statements are based on certain assumptions that management believes are reasonable at the time such statements are made, including, without limitation: that the Company will be able to use the proceeds of the Loans as currently anticipated; that the Company will be able to satisfy its obligations under the Loans; that the Company will have access to additional financing, if required, on acceptable terms; and that the Company will be able to continue to advance its business objectives and research and development activities.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements, as actual results may differ materially from those expressed or implied herein.

The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update or revise such statements except as required by applicable securities laws.